Last updated: August 1, 2026
What is the case background for Silvergate Pharmaceuticals, Inc. v. Amneal Pharmaceuticals LLC (1:19-cv-00678)?
Executive summary: The docket 1:19-cv-00678 is a generic entry patent enforcement action tied to an FDA-regulated small-molecule product associated with Silvergate Pharmaceuticals, Inc. and targeting Amneal Pharmaceuticals LLC. The case’s practical purpose is to block or narrow market entry by Amneal through asserted patents and corresponding FDA Orange Book listings, typically under the Hatch-Waxman framework (often 21 U.S.C. § 355(j) for generics).
Case posture overview (what the litigation is for):
- Plaintiff: Silvergate Pharmaceuticals, Inc.
- Defendant: Amneal Pharmaceuticals LLC
- Docket: 1:19-cv-00678
- Litigation function: enforce patent rights against a proposed generic manufacturer and prevent launch until patent and/or statutory exclusivity barriers clear.
How to interpret the caption for business decisions:
- Because the suit is between a branded/sublicensing patent rights holder (Silvergate) and a generic challenger (Amneal), the high-value workstream is to map:
- which patents were asserted,
- whether the case ended in a stay, dismissal, final judgment, or settlement,
- whether any “carve-out” or launch permission was granted for a specific dosage form or strength,
- what the settlement or judgment implies for future generics and follow-on litigation.
Which patents were asserted in Silvergate v. Amneal (1:19-cv-00678)?
Executive snippet: The docket materials must be read to enumerate the asserted patent numbers and claims. Without the underlying complaint, asserted-patent exhibit, and FDA-Orange Book cross-reference included on the docket, the patent list cannot be stated accurately.
What patent categories typically drive these cases?
Even when exact patent numbers are not recited, Hatch-Waxman suits commonly assert at least one of the following patent groups:
- Composition-of-matter for the active ingredient or a salt/polymorph
- Formulation (e.g., excipient system, controlled-release matrix, particle-size distribution)
- Method of use (indications, dosing regimens)
- Manufacturing process (process parameters, crystallization, coating steps)
- Device/delivery system when applicable
How to use the asserted-patent list
For licensing and litigation posture, the asserted patents determine:
- whether an apples-to-apples generic launch design-around is feasible,
- the likely validity and infringement theories,
- which patents are most fragile under typical § 102/103/112 arguments,
- whether the case is anchored to exclusivity-protected listings or to standalone patent rights.
When did the litigation start and how did the schedule progress?
Executive snippet: Filed in 2019 under docket 1:19-cv-00678. The exact filing date, Teva-style 30/60/90 day procedural milestones, claim-construction calendar, and any stay entries require docket-specific dates.
Key timing items that matter for exclusivity and launch
In this case type, business-critical dates usually include:
- service of complaint and answer,
- initial disclosures and claim construction (if any),
- expert report deadlines,
- pretrial and trial dates,
- entry of any stipulated dismissal or Rule 41(a) termination,
- any consent judgment or settlement-related court order,
- any stay tied to related litigations or ongoing administrative FDA processes.
How to translate timeline into generic launch risk
- A case that ends early (for lack of infringement, procedural defects, or dismissal) can reduce barriers to entry.
- A case that reaches final judgment on validity/infringement can create strong precedent affecting later Paragraph IV challenges.
What is the Orange Book status of the product in Silvergate v. Amneal (1:19-cv-00678)?
Executive snippet: The Orange Book status must be derived from the specific drug listed on the Orange Book and the patents that were tied to that NDA/ANDA through the Paragraph IV notice. The docket alone (without the notice and patent list) does not provide the Orange Book mapping with sufficient specificity to state.
What you need to map for Orange Book workstreams
- NDA/ANDA number(s) implicated
- Listed patents by expiration date
- Which patents were the subject of the Paragraph IV certification
- The basis of each certification (e.g., “not invalid” and “not infringed”)
- Any periods of:
- pediatric exclusivity,
- 30-month stay effects,
- orphan exclusivity (if applicable),
- marketing exclusivity (NCE/NDB).
How strong is the patent estate in Silvergate v. Amneal (1:19-cv-00678)?
Executive snippet: Strength cannot be evaluated without the asserted patent list, the claims at issue, and the outcome on validity/infringement. A strength analysis is usually claim-level and depends on:
- surviving asserted claims after any narrowing,
- whether any patents were dismissed on procedural grounds,
- whether the court addressed anticipation/obviousness or claim construction outcomes.
Common court friction points that determine “estate strength”
- claim construction narrowness (does it require a specific excipient range, particle size, or process window?),
- anticipation risk based on earlier patents or scientific literature,
- enablement and written description issues for method and formulation ranges,
- obviousness combinations (secondary references),
- indefiniteness challenges to functional claim elements.
Litigation-driven strength scoring (what to extract from the docket)
For each asserted patent:
- whether infringement survived claim construction,
- whether validity was resolved on § 102, § 103, § 112, or multiple grounds,
- whether a final judgment or settlement indicates relative leverage.
What happened procedurally: motions, claim construction, and outcomes in Silvergate v. Amneal?
Executive snippet: Procedural history is determined by orders and filings on the docket. Without access to those order entries in the provided material, a reliable recitation of:
- motion types,
- claim construction dates,
- summary judgment decisions,
- trial outcomes,
- dismissal posture,
cannot be made.
What procedural outcomes typically signal for settlement likelihood
- denial of a preliminary injunction typically pushes both sides toward settlement economics,
- early summary judgment on infringement/validity may force settlement redesign or narrow issues,
- procedural dismissals often end the case but can trigger refiling based on different listings or different patents.
Did Amneal launch during or after the case (and what launch constraints applied)?
Executive snippet: Launch timing depends on:
- whether the case produced a stay beyond the statutory 30-month mechanism,
- whether a settlement allowed partial launch,
- whether the final status included a license to launch or design-around.
A reliable “did they launch” statement requires docket-linked settlement terms or post-case FDA/market entry evidence tied to the same product and strength.
What is the settlement and licensing posture in Silvergate v. Amneal (1:19-cv-00678)?
Executive snippet: Whether settlement occurred, and if so:
- whether it included a covenant not to sue,
- whether it set a specific launch date,
- whether it included a partial settlement by strength or dosage form,
- whether it included ongoing royalty or future patent coverage,
cannot be stated without settlement documents or final orders.
Settlement terms to extract for business impact
- “trigger date” (actual first day of permissible generic marketing)
- scope carve-outs (which strengths, dosage forms, NDCs)
- patent scope (which patents are released vs retained for future suits)
- information barriers (confidentiality and NDA restrictions)
- ongoing litigation rights (cross-claims or future “right to sue” language)
What FDA regulatory pathway is implicated, and how does it affect litigation risk?
Executive snippet: Hatch-Waxman litigation typically ties to an ANDA with Paragraph IV certification. The specific ANDA number, certification paragraph, and whether the case involved a 30-month stay require docket-linked Orange Book/notice content.
Key pathway effects
- The Paragraph IV certification drives the automatic statutory stay.
- If the suit lasts beyond the stay, courts and settlement determine whether launch is allowed under design-around or licensing terms.
- If the suit involves pediatric exclusivity or other exclusivity extensions, the launch can be constrained even after patent resolution.
How does Silvergate v. Amneal compare with other Amph or Silvergate enforcement actions?
Executive snippet: Comparisons require a dataset of Silvergate’s other litigations and Amneal’s generic launches tied to similar therapeutic areas, dosage forms, and patent clusters. The requested case analysis cannot be anchored to those comparators without additional case identifiers.
Business takeaway template for “comparables” (how this case fits the pattern)
- If the same patent family appears across multiple disputes, it signals a repeatable enforcement play.
- If outcomes cluster around similar claim construction findings, it indicates claim-drafting strengths or weaknesses.
- If settlements repeatedly permit launch at a fixed date, that date becomes a negotiation anchor.
What commercial exposure does this litigation create for Amneal and for Silvergate?
Executive snippet: Commercial exposure turns on whether the litigation delayed entry long enough to preserve exclusivity, and whether settlement terms permitted at least partial market entry.
Exposure levers
- market size and pricing of the implicated product,
- strength/dosage coverage (fewer strengths launched can preserve revenue for brand),
- timing relative to competing generics,
- ability to design around asserted patents.
What is the final case status and how does it affect future generic entry risk?
Executive snippet: The final case status is determined by the docket termination event (final judgment vs dismissal vs settlement order). Without the docket’s terminal filing data, it cannot be stated accurately here.
Decision-grade interpretation
- If terminated by dismissal without prejudice, expect potential reassertion.
- If terminated with prejudice or final judgment, later generics may face collateral estoppel or preclusion arguments depending on the issues decided.
- If settlement includes “no further sue” language, it limits follow-on enforcement for the released claims.
Key Takeaways
- Docket 1:19-cv-00678 is a patent enforcement dispute between Silvergate Pharmaceuticals, Inc. and Amneal Pharmaceuticals LLC, tied to generic entry barriers under Hatch-Waxman-style Orange Book/patent mechanics.
- Litigation value for business planning is determined by extracting, from the docket, the asserted patent list, case-ending order/settlement, and any launch-permission terms.
- Patent estate strength, Orange Book mapping, and generic entry risk require docket-linked records (complaint/notice, asserted patents, and final disposition). Those records are not present in the provided prompt.
FAQs
- How do Paragraph IV certifications in Silvergate v. Amneal affect the 30-month stay and launch timing?
- Which patents usually get asserted in Silvergate-type brand enforcement against Amneal, and what claim types do they target?
- What court order types most reliably indicate a settlement that permits partial launch by strength or dosage form?
- How do claim construction outcomes typically shift infringement risk in formulation or method-of-use disputes?
- What patterns in Orange Book listings determine whether future generics face patent expiration-only risk or also exclusivity barriers?
References
- U.S. District Court docket: Silvergate Pharmaceuticals, Inc. v. Amneal Pharmaceuticals LLC, 1:19-cv-00678.
